AbbVie (ABBV) Share-based Compensation (2012 - 2026)
AbbVie (ABBV) posted quarterly Share-based Compensation of $444.0 million for Q1 2026, up 8.29% year-over-year from $410.0 million in Q1 2025, and up 182.8% quarter-over-quarter from $157.0 million in Q4 2025.
AbbVie (ABBV) Share-based Compensation (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Share-based Compensation for 15 consecutive years, with $444.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 8.29% year-over-year to $444.0 million; the TTM figure through Mar 2026 stood at $989.0 million (up 1.64% YoY), while the FY2025 annual figure was $955.0 million, up 4.83% from the prior year.
- Share-based Compensation climbed to $444.0 million in Q1 2026 per ABBV's latest filing, from $157.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $444.0 million in Q1 2026 and bottomed at $107.0 million in Q2 2022.
- Historically, Share-based Compensation has averaged $219.3 million across 5 years, with a median of $179.0 million in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 32.7% — and 2023, when it soared 67.29%.
- AbbVie's Share-based Compensation stood at $132.0 million in 2022, then decreased by 5.3% to $125.0 million in 2023, then jumped by 31.2% to $164.0 million in 2024, then fell by 4.27% to $157.0 million in 2025, then soared by 182.8% to $444.0 million in 2026.
- Business Quant data shows ABBV's Share-based Compensation at $444.0 million in Q1 2026, $157.0 million in Q4 2025, and $209.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.91 Bn | 632.15 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 469.40 Bn | 462.83 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 375.75 Bn | 368.61 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 303.13 Bn | 295.44 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.65 Bn | 252.75 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.26 Bn | 222.27 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 182.12 Bn | 178.95 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 159.46 Bn | 147.76 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 106.21 Bn | 102.04 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.16 Bn | 47.78 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 166.00 Mn |
| Jun 30, 2026 | 166.00 Mn |
| Mar 31, 2026 | 444.00 Mn |
| Mar 31, 2026 | 444.00 Mn |
| Dec 31, 2025 | 157.00 Mn |
| Dec 31, 2025 | 157.00 Mn |
| Sep 30, 2025 | 209.00 Mn |
| Sep 30, 2025 | 209.00 Mn |
| Jun 30, 2025 | 179.00 Mn |
| Jun 30, 2025 | 179.00 Mn |
| Mar 31, 2025 | 410.00 Mn |
| Mar 31, 2025 | 410.00 Mn |
| Dec 31, 2024 | 164.00 Mn |
| Dec 31, 2024 | 164.00 Mn |
| Sep 30, 2024 | 181.00 Mn |
| Sep 30, 2024 | 181.00 Mn |
| Jun 30, 2024 | 218.00 Mn |
| Jun 30, 2024 | 218.00 Mn |
| Mar 31, 2024 | 348.00 Mn |
| Mar 31, 2024 | 348.00 Mn |